Behind Nina Capital: Healthcare Innovators
In 2019, Marta-Gaia Zanchi, a former director of Stanford Biodesign’s Digital Health initiatives, and Marc Subirats, co-founder of Advance Medical, sold to Teladoc Health for $352M in 2018, founded Nina Capital. Since its inception, the firm has invested in 50 companies across nearly 20 countries, impacting over 10 million people through healthcare technology innovations.
Nina Capital’s Fund III: What Do We Know So Far?
The completion of Fund III, anchored by contributions from a diverse range of limited partners, underscores the global belief in Nina Capital’s mission: to empower need-driven founders reshaping healthcare systems with information technology.
Portfolio Highlights: Mindpeak and Sober Sidekick
Nina Capital’s track record speaks for itself. Startups from Fund I achieved an above 80% graduation rate from seed to the next stage. Fund II portfolio companies collectively grew revenue almost fivefold within two years of initial investment. This momentum stems from the firm’s specialized team and ability to identify and scale impactful healthcare innovations.
Nina Capital’s Fund III: Investments and Focus
The fund is designed to invest from pre-seed to Series A, writing cheques between €250,000 and €1.5 million for startups across Europe, North America, Israel, and Australia for the first time. Investments will concentrate on Clinical Innovation and Education (diagnostics, medical devices, and clinician training), Healthcare Infrastructure (data-driven processes in preclinical R&D, clinical trials, pharmaceutical logistics, and manufacturing), and Clinical Pathways and Health Data (care delivery through tech-enabled services and operational efficiencies).
Conclusion
Nina Capital’s Fund III is a testament to the growing importance of healthcare innovation, driven by AI, personalization, and digital solutions. The fund’s focus on early-stage investments, international ambition, and market-specific expertise positions it as a key player in the European venture capital landscape.
FAQs
Q: What is Nina Capital’s focus?
A: Nina Capital focuses on early-stage investments in healthcare technology startups with international ambitions.
Q: What is the fund size of Nina Capital’s Fund III?
A: The fund is €50 million.
Q: Who are the limited partners of Nina Capital’s Fund III?
A: The fund is anchored by LPs, including Seven Two Partners, family offices, and high-net-worth individuals from the US and Europe.
Q: What is the investment range for Nina Capital’s Fund III?
A: The fund will invest between €250,000 and €1.5 million in startups across Europe, North America, Israel, and Australia.
